Filed: 5 May 21, 2:46pm
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2021
Commission File Number 001-15170
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Results of Annual General Meeting
GlaxoSmithKline plc ('GSK') held its Annual General Meeting ('AGM') at 2.30pm on Wednesday 5 May 2021.
The statement made by the Chairman at the AGM will shortly be available to view on GSK's website at www.gsk.com.
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
The table below shows the results of the poll on all 22 resolutions. The full text of the resolutions is contained in the Notice of AGM published on 30 March 2021, which is available on GSK's website at www.gsk.com.
Total votes for(1)(2)
Total votes against(2)
|%||Total votes cast|
|1||Receive and adopt the 2020 Annual Report||3,475,135,362||98.81||41,757,734||1.19||3,516,893,096||11,603,440|
|2||Approve the Annual report on remuneration||3,272,132,033||93.14||240,932,159||6.86||3,513,064,192||15,444,148|
|3||Re-election of Sir Jonathan Symonds||3,499,343,831||99.52||16,763,629||0.48||3,516,107,460||12,371,547|
|4||Re-election of Dame Emma Walmsley||3,507,017,955||99.68||11,159,384||0.32||3,518,177,339||10,359,075|
|5||Re-election of Charles Bancroft||3,506,975,009||99.74||9,026,131||0.26||3,516,001,140||12,472,435|
|6||Re-election of Vindi Banga||3,496,064,409||99.43||19,904,292||0.57||3,515,968,701||12,509,463|
|7||Re-election of Dr Hal Barron||3,507,018,967||99.69||10,733,599||0.31||3,517,752,566||10,738,305|
|8||Re-election of Dr Vivienne Cox||3,497,451,811||99.46||18,813,391||0.54||3,516,265,202||12,207,081|
|9||Re-election of Lynn Elsenhans||3,434,728,312||97.69||81,301,678||2.31||3,516,029,990||12,440,783|
|10||Re-election of Dr Laurie Glimcher||3,508,174,526||99.77||7,947,259||0.23||3,516,121,785||12,353,907|
|11||Re-election of Dr Jesse Goodman||3,506,872,640||99.74||9,131,605||0.26||3,516,004,245||12,467,159|
|12||Re-election of Iain Mackay||3,501,889,913||99.56||15,637,087||0.44||3,517,527,000||10,951,129|
|13||Re-election of Urs Rohner||3,484,061,208||99.10||31,702,634||0.90||3,515,763,842||12,752,529|
|14||Re-appointment of the auditor||3,512,936,007||99.84||5,521,996||0.16||3,518,458,003||10,024,350|
|15||Remuneration of the auditor||3,511,280,034||99.82||6,176,678||0.18||3,517,456,712||11,022,183|
|16||Authority for the company to make donations to political organisations and incur political expenditure||3,440,815,513||98.36||57,276,887||1.64||3,498,092,400||30,393,327|
|17||Authority to allot shares||3,362,807,250||95.66||152,632,653||4.34||3,515,439,903||13,038,799|
Disapplication of pre-emption rights - general power(4)
Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(4)
Authority for the company to purchase its own shares(4)
|21||Exemption from statement of senior statutory auditor's name||3,477,878,016||99.47||18,543,893||0.53||3,496,421,909||31,294,363|
Authority for reduced notice of a general meeting other than an AGM(4)
The "for" votes include those giving the Chairman discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions.
Votes "for" and "against" are expressed as a percentage of the total votes cast.
A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
Indicates Special Resolutions requiring a 75% majority.
The following table provides further relevant information:
|Issued share capital (excluding Treasury Shares)||5,031,444,276||5,017,091,542|
|Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)||70.11%||72.60%|
|Total shareholder population||100,906||105,353|
|Total number of proxies lodged||6,089||6,268|
|% of shareholders who lodged proxies||6.03%||5.95%|
The above poll results will shortly be available on the company's website at www.gsk.com. In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the UK Listing Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
V A Whyte
5 May 2021
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
|Date: May 05, 2021|
By:/s/ VICTORIA WHYTE
|Authorised Signatory for and on|
|behalf of GlaxoSmithKline plc|